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INTRODUCTION 
The International Classification of Diseases classifies rubella as two 
diseases: Rubella (ICD-9 056; ICD-10 B06) and Congenital Rubella Syndrome 
(ICD-9 771.0; ICD-10 P35.0) (World health organization 1993, Benenson 
1995). 
HISTORY OF RUBELLA 
The earliest description of rubella dates back to the 1700s when two 
German physicians De Bergen in 1752 and Orlow in 1758 described the 
clinical manifestations of the disease. At that time the clinical manifestations 
were considered to be a variant of measles and scarlet fever and was called the 
third Disease. It was not until 1814, that the illness was described as a 
distinct entity for the first time by another German physician George de Maton 
who called it RÔTHELN(1). Because of the strong German connection the 
disease was also called German measles or Three-day measles due to the 
similarity of the illness to measles. In 1866 the disease was renamed Rubella 
by Henry meaning Little Red in Latin (2). 
In 1914 Hess postulated a viral etiology based on his work with 
monkeys. Hiro and Tasaka in 1938 documented the viral etiology by passing 
the disease to children using filtered nasal washings from acute cases (2). The 
illness was merely considered a mild illness of children and adults with a 
prodrome of cold like symptoms. When Australia faced an epidemic of 
Rubella in 1940-41, it was even debated that the illness was due to a mutant 
strain of the virus as many adults were infected and there was high incidence 
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of associated arthritis and arthralgia. After that epidemic in 1941, Dr Norman 
Gregg a senior ophthalmologist reported an out break of unusual type of 
cataract where all the layers except the outermost layer of the lens were 
affected, with other associated defects comprising of a variety of heart 
defects predominantly patent ductus arteriosus. He presented that The 
remarkable similarity of the opacities in the lens, the frequency of an 
accompanying affection of the heart and the widespread geographical 
incidence of the cases suggested there was some common factor in the 
production of the diseased condition, and suggested it was the result of some 
constitutional condition of toxic or infective nature rather than of a purely 
development defect and he added that maternal rubella infection in early 
pregnancy was the cause of the babies defects . The recognition of 
association of rubella to these birth defects by Dr. Gregg is considered 
remarkable. 
In 1962 rubella virus was first isolated by Parkman and Weller and soon 
this was followed by the development of the vaccine, which was licensed in 
1969, and once the human diploid cell cultured RA 27/3 strain vaccine was 
licensed for use, all other vaccines strains were discontinued. 
THE VIRUS 
The Rubella Virus (RV) is a human-specific, non-arthropod borne, 
lipid-enveloped, positive-sense, single-stranded RNA virus. It is the only 
member of the genus Rubivirus in the Togaviridae family. The mature RV 
virion is a round or ovoid particle approximately 60 nm in diameter. The RV 
virion contains a RNA genome enclosed in an icosahedral capsid composed of 
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protein C (33kDa). Surrounding this nucleo-capsid is a lipid bilayer, in which 
viral glycoproteins E1 (58 kDa) and E2 (42 to 47 kDa) are embedded (3). The 
protein C, glycoproteins E1 and E2 are the three structural proteins and there 
are two non-structural proteins NS1 and NS2. RV is relatively unstable and is 
rapidly inactivated by 70% alcohol, ethylene oxide, formalin, ether, acetone, 
chloroform, free chlorine, deoxycholate, beta-propiolactone, ultraviolet light, 
extreme pH (<6.8 or >8.1), heat (>56°C), and cold (from -10 to -20°C). It is 
resistant to thiomersal and is stable at temperatures of -60°C or less. 
The virus replication cycle is confined to the cytoplasm of the infected 
cells. RV considered non-cytopathogenic to most mammalian cells, induces a 
cytopathogenic effect only in continuous cell lines such as RK13 (rabbit 
kidney) and Vero. Immunofluourescense is used to identify the presence of the 
virus in culture. The humoral immune response to RV is predominantly to the 
E1 glycoprotein and persists indefinitely after infection (4). 
E1 has 6 distinct antigenic determinants, 4 associated with 
haemagglutination and 2 with neutralization. Though sequencing studies have 
recognized two genotypes; one from Europe, North America and Japan and 
another identified from isolates in India and China, RV is antigenically stable 
and hence does not pose a problem for serological diagnosis or for vaccination 
(5). 
There is only one serotype of the rubella virus (6). Humans are the only 
known natural hosts for the RV. The lack of animal models to reproduce the 
cytopathic effects of rubella virus has hindered significant research 
opportunities and understanding of the teratogenic properties of the virus. 
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Hence, unlike the situation for most human teratogens, animal models of CRS 
are not particularly useful and have not contributed much to the understanding 
of the pathogenesis of the defects. However, in contrast to the situation for 
other human teratogens, there is good histopathology of infected abortuses, 
and these have provided valuable information on the pathogenesis of the 
abnormalities (7).  
EPIDEMIOLOGY 
OCCURRENCE 
Rubella occurs worldwide. 
RESERVOIR 
Rubella is a human disease. There is no known animal reservoir. 
Although infants with CRS may shed rubella virus for an extended period, a 
true carrier state has not been described. 
TRANSMISSION 
Rubella is spread from person-to-person via airborne transmission or 
droplets shed from the respiratory secretions of infected persons. There is no 
evidence of insect transmission. Rubella may be transmitted by subclinical or 
asymptomatic cases (up to 50% of all rubella virus infections). 
TEMPORAL PATTERN 
In temperate areas, incidence is usually highest in late winterearly 
spring. Epidemics occur every 5-9 years. However, the extent and periodicity 
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of rubella epidemics is highly variable in both developed and developing 
countries. The reasons for this are not known. Before the introduction of large-
scale rubella vaccination, the average age at which children were infected 
varied between 6-12 years in industrialized areas and 2-8 years in urban areas 
of developing countries.   
COMMUNICABILITY 
Rubella is only moderately contagious. The disease is most contagious 
when the rash is erupting, but virus may be shed from 7 days before to 57 
days or more after rash onset. 
Infants with CRS shed large quantities of virus from body secretions for 
up to one year and can therefore transmit rubella to persons caring for them 
who are susceptible to the disease. 
RUBELLA  
Rubella is a common cause of maculopapular rash illness with fever 
during childhood. In the industrialized world where the routine vaccination 
against rubella is in place, the occurrence of rubella infection is noted 
predominately in adolescents and young adults; but in India where rubella 
vaccination is not part of the national immunization programme, the disease is 
prevalent across all age groups from early childhood through adolescence to 
adulthood, though the pre-school children are relatively spared. 
A history of exposure may not be present. The incubation period is 
usually 14 days with a range of 12 days to 23 days. The illness in childhood is 
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usually without prodromal symptoms unlike in adults who may experience a 
15 day prodrome before the onset of rash. The signs and symptoms include 
1. Eye pain on lateral and upward eye movement (particularly 
troublesome complaint) 
2. Conjunctivitis 
3. Sore throat 
4. Headache 
5. General body aches and malaise 
6. Low-grade fever 
7. Chills 
8. Anorexia 
9. Nausea 
10. Tender post-auricular, occipital and posterior cervical 
lymphadenopathy is characteristic and precedes the rash by 5-10 
days. 
11. Forchheimer sign (an enanthem observed in 20% of patients with 
rubella during the prodromal period; can be present in some 
patients during the initial phase of the exanthem; consists of 
pinpoint or larger petechiae that usually occur on the soft palate) 
12. Arthralgia or arthritis, more common in women than men, may 
occur in up to 70% of adult women with rubella. 
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13. Rare complications include thrombocytopenic purpura and 
encephalitis. 
The exanthema (rash) of rubella consists of a discrete rose pink 
maculopapular rash ranging from 1-4 mm. Rash in adults may be quite 
pruritic. The synonym 3-day measles derives its name from the typical 
course of rubella exanthema that starts initially on the face and neck and 
spreads centrifugally to the trunk and extremities within 24 hours. It then 
begins to fade on the face on the second day and disappears throughout the 
body by the end of the third day.  The clinical diagnosis of rubella is 
unreliable, as it is one of many diseases causing maculopapular rash with 
fever. The differential diagnosis includes 
1. Measles, 
2. Dengue, 
3. Parvovirus B19, 
4. Human herpes virus 6, 
5. Coxsackie, 
6. Echovirus, 
7. Ross River, 
8. Chikungunya, 
9. Entero and adenoviruses, 
10. Streptococcus group A (beta hemolytic). 
Measles is most frequently associated with cough, coryza, and 
conjunctivitis, though these are relatively nonspecific symptoms common to a 
number of viral infections. Joint symptoms are seen in up to 60% of adult 
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women with rubella, but joint symptoms are also frequent with parvovirus B19 
infection and with dengue and other arboviral diseases. Post-auricular 
lymphadenopathy is associated with rubella and roseola infantum (usually seen 
in children < 4 years); thus, the differential diagnosis of rubella remains 
difficult in young children. For these reasons, confirmation of rubella is not 
possible without laboratory testing (8).  
CONGENITAL RUBELLA INFECTION (CRI) AND CONGENITAL 
RUBELLA SYNDROME (CRS) 
Rubella virus infection imparts a public health concern only when 
pregnant women and women of the childbearing age contract the disease, 
because of the teratogenic potential of the rubella virus (9). 
Congenital Rubella Infection (CRI) encompasses all outcomes of 
intrauterine rubella infection including abortion, stillbirth, congenital defects 
noticed soon after birth or that which develops as a late-manifestation referred 
to as Congenital Rubella Syndrome (CRS) and asymptomatic rubella infection. 
When a pregnant woman contracts the disease, the average risk to the 
fetus all through the pregnancy is 45%. In the first trimester there is almost 
81% chance of the fetus being infected. The rate drops to 54% for weeks 13 to 
16 and the lowest risk period is between 23-26 weeks at 25%. During the last 
10 weeks the rate of infection rises again to be 60% between 31 and 36 weeks 
and it was 100% beyond 36 weeks of gestation (10).  
Rubella embryopathy almost exclusively results from first trimester 
maternal infection (11) and is greatest in the first 8 weeks of pregnancy. 
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Cardiac and eye defects are more likely to result when maternal infection is 
acquired during the first 8 weeks of pregnancy (i.e.) during the critical phase 
of organogenesis whereas retinopathy and hearing defects are more evenly 
distributed throughout the first 16 to 20 weeks of gestation. After the first 
trimester, the virus is isolated infrequently from the neonates, probably 
because fetal immune mechanisms can be activated and infection can be 
terminated. 
Following intrauterine infection in early pregnancy the virus persists 
throughout the gestation. Virus can also be recovered from nasopharyngeal 
secretions, urine, stools and CSF from survivors. However, by the age of 3 
months the proportion-excreting virus declines to 50-60% and by 1 year, 10%.   
MAIN CLINICAL MANIFESTATIONS OF CONGENITAL RUBELLA 
(12,13) 
The clinical manifestations of CRS can be transient, developmental or 
permanent 
 
 
CATEGORY 
 
SPECIFIC MANIFESTATION 
GENERAL Fetal loss (spontaneous abortion and stillbirth) 
Low birth weight 
AUDITORY SYSTEM Sensorineural deafness 
Central auditory deafness 
Speech defects 
CARDIOVASCULAR 
SYSTEM 
 
Patent ductus arteriosus 
Pulmonary stenosis 
Coarctation of aorta 
Ventricular septal defects 
Complex congenital heart disease 
Myocarditis 
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OCULAR SYSTEM Pigmented retinopathy 
Cataracts: pearly, dense, nuclear 
50% bilateral, very often with retinopathy 
Microphthalmos 
Cloudy cornea 
Glaucoma 
HEMATOLOGICAL 
 
Thrombocytopenia with or without purpura 
Hemolytic anaemia 
Altered blood group expression 
CENTRAL NERVOUS 
SYSTEM 
Meningoencephalitis 
Microecphaly 
Intracranial calcifications 
Electro encephalographic abnormalities 
Mental retardation 
Behavior disorders 
Autism 
Chronic progressive panencephalitis 
SKIN Blue berry muffin spots 
Chronic rubelliform rash 
Dermatoglyphic abnormalities 
IMMUNOLOGICAL Hypogammaglobulinaemia 
Lymphadenopathy 
Thymic hypoplasia 
ENDOCRINE Insulin dependent Diabetes Mellitus 
Hyperthyroidism or hypothyroidism 
Growth hormone deficiency 
GENITOURINARY Cryptorchidism 
Polycystic kidney disease 
LIVER Hepatosplenomegaly 
Jaundice 
Hepatitis 
LUNGS Interstitial pneumonia 
BONE Radiographic lucencies 
Large anterior fontanelle 
Micrognathia 
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IMMUNE RESPONSE IN RUBELLA 
The humoral immune response to rubella infection has been well 
studied. Rubella specific IgM is diagnostic of acute infection; IgM usually 
appears within four days after onset of the rash and can persist up to 4-12 
weeks. Rubella-specific IgG is a long-term marker of previous rubella 
infection; IgG begins to rise after the onset of the rash, peaks about four weeks 
later, and generally lasts for life (14). 
The natural infection with wild virus was shown to induce more 
vigorous immune response than a vaccine induced response (15). Serology 
remains the method of choice for diagnosis of rubella infections and for 
determination of susceptibility. 
The serum immune response in CRS differs from that seen in rubella 
(and from many other viral diseases). At birth, the serum of an infant with 
CRS contains maternally derived rubella-specific IgG antibodies as well as 
IgG and IgM antibodies synthesized by the fetus. Maternal rubella-specific 
IgG is also found in normal infants born to women who are immune to rubella. 
Therefore, rubella-specific IgM is used to diagnose congenital rubella 
infection in infants. In infants with CRS, rubella-specific IgM can be detected 
in nearly 100% at age 0-5 months; about 60% at age 6-12 months; and 40% at 
age 12-18 months; IgM is rarely detected after age 18 months (16). 
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DIAGNOSIS OF RUBELLA AND CONGENITAL RUBELLA 
SYNDROME 
Either one of the following is necessary for diagnosis of Rubella or 
CRS 
• Demonstration of a rubella-specific IgM antibody 
• Demonstration of infant IgG rubella antibody level that persists 
at a higher level and for a longer time than expected from 
passive transfer of maternal antibody (i.e., rubella titre that does 
not drop at the expected rate of a twofold dilution per month) 
• Isolation of rubella virus, which can be obtained from nasal, 
blood, throat, urine, or cerebrospinal fluid specimens (best 
results come from throat swabs) 
• Detection of virus by RT-PCR can be used to detect the presence 
of rubella virus after growth in tissue culture or directly in 
clinical specimens. 
In 1998 the World Health Organization (WHO) Department of 
Vaccines and Biologicals, in collaboration with WHO regional offices and 
with specialists from the WHO Programme for the Prevention of Blindness 
and Deafness, developed standard case definitions for Rubella and CRS to be 
used for surveillance (17,18,19) 
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RUBELLA  
a. Suspected rubella case:  A suspected rubella case is any patient of any age 
in whom a health worker suspects rubella. A health worker should suspect 
rubella when a patient presents with fever, maculopapular rash, and one or 
more of the following: cervical adenopathy, suboccipital adenopathy, 
postauricular adenopathy, or arthralgia/arthritis. 
b. Clinically or Laboratory confirmed rubella case: A laboratory-confirmed 
rubella case is a suspected case with a positive blood test for rubella-
specific IgM. The blood specimen should be obtained within 28 days after 
the onset of rash. 
c. Epidemiologically confirmed rubella case: An epidemiologically 
confirmed rubella case is a patient who meets the suspected case definition 
and is epidemiologically linked to a laboratory confirmed case. 
CONGENITAL RUBELLA SYNDROME 
a. Suspected CRS case: 
A suspected case is any infant less than one year of age in whom 
1. There is a maternal history of suspected or confirmed rubella 
during pregnancy. 
2. When the infant presents with heart disease, and/or suspicion of 
deafness, and/or one or more of the following eye signs: 
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• White pupil (cataract); 
• Diminished vision; 
• Pendular movement of the eyes (Nystagmus); 
• Squint; 
• Small eye ball (Microphthalmia); 
• Large eyeball (congenital glaucoma). 
b. Clinically confirmed CRS case: 
A clinically-confirmed case is one in which a qualified physician 
detects two of the complications in group (a) OR one from group (a) and one 
from group (b): 
(a) Cataract(s) and/or congenital glaucoma; congenital heart disease; 
loss of hearing; pigmentary retinopathy. 
(b) Purpura; hepatosplenomegaly; microcephaly; developmental 
delay; meningoencephalitis; radiolucent bone disease; jaundice 
with onset within 24 hours after birth. 
c.  Laboratory-confirmed CRS case: 
A laboratory-confirmed CRS case is an infant with a positive blood test 
for rubella specific IgM who has clinically-confirmed CRS. 
d.  Congenital rubella infection (CRI): 
An infant with a positive blood test for rubella IgM who does not have 
clinically confirmed CRS is classified as having congenital rubella infection 
(CRI). 
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RUBELLA VACCINE 
The first vaccine was developed in the early 60's (HPV77.DE5 and 
Cendehill) and was licensed for use in 1969. In 1979 the HPV77.DE5 strain 
was replaced with RA27/3 and Cendehill is no longer available. Vaccine is 
available, either as single antigen vaccine or combined with measles vaccine 
(MR), mumps vaccine or measles and mumps vaccine (MMR). Most of the 
currently licensed vaccines are based on the live, attenuated RA 27/3 strain of 
rubella virus, propagated in human diploid cells. The RA27/3 vaccine is highly 
stable at 70°C. When stored at 4°C, its potency is maintained for at least five 
years. The vaccine should be stored at 28°C and protected from light. Each 
dose of this vaccine, which is given by the subcutaneous route, contains a 
defined number of active virus particles (>1000 TCID 50). Other attenuated 
rubella vaccine strains, such as the Matsuba, DCRB 19, Takahashi, Matsuura 
and TO-336 strains are used primarily in Japan; the BRD-2 strain is used in 
China. 
Rubella vaccine is usually administered at age 1215 months, but can 
also be administered to children as young as nine months of age. In most 
countries, the vaccine is given as MR or MMR, and the age of administration 
is chosen based on the appropriate age for measles vaccination. It may also be 
administered to older children, adolescents, students, childcare personnel, 
health care workers, military personnel and adult men in contact with women 
of childbearing age. Rubella vaccination should be avoided in pregnancy 
because of the theoretical (but never demonstrated) teratogenic risk. 
Consequently, there is no need to screen women for pregnancy before rubella 
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vaccination. If pregnancy is being planned, then an interval of one month 
should be observed after rubella immunization. Rubella vaccination during 
pregnancy is not an indication for abortion. Although the virus is excreted by 
vaccinated, it is not transmitted to susceptible contacts. 
Persons with a history of anaphylactic reaction to neomycin or an 
anaphylactic reaction after a previous dose of rubella vaccine should not 
receive the vaccination. Rubella vaccines should not be given to persons 
suffering from advanced immunodeficiency including congenital immune 
disorders, malignancies and immunosuppressive therapy. However, 
asymptomatic HIV-positive persons can be immunized. Children with 
malignant disease or who have had a bone marrow transplant should be 
immunized against rubella six months after immunosuppressant treatment is 
stopped. Vaccination should be postponed if the potential vaccinee has a 
serious illness. Persons with active tuberculosis should not be vaccinated until 
treatment has been established. Rubella antibodies present in blood products 
may interfere with rubella vaccination. Therefore, persons who received blood 
products should wait at least three months before vaccination and if possible, 
blood products should be avoided for up to two weeks post-vaccination. 
Generally, the adverse events following vaccination with the RA27/3 
rubella vaccine are mild, particularly in children. Most of the available data on 
adverse events are for the MMR combination. Common adverse events include 
pain, redness and induration at the site of injection. Low-grade fever and rash, 
lymphadenopathy, myalgia and paraesthesia are commonly reported. Joint 
symptoms tend to be rare in children (0%3%) and in men, but are common 
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among vaccinated adolescent and adult females; they include arthralgias (25%) 
and arthritis (10%) that usually last from a few days to two weeks. These 
transient reactions seem to occur in non-immune individuals only, for whom 
the vaccine is important. Thus, fear of unjustified side effects should not 
prevent vaccination of women with uncertain rubella immune status. As there 
is no harm in vaccinating already immune individuals, serological testing 
before immunization is not necessary. Although concerns have been raised that 
rubella vaccination of adult women might occasionally lead to chronic 
arthritis, large epidemiological studies have not supported a role for rubella 
vaccine in chronic joint disease. Thrombocytopenia is rare and has been 
reported in less than 1 case per 30,000 doses administered. Anaphylactic 
reactions are rare after RA27/3 vaccines. 
The RA27/3 vaccine is highly efficacious. In clinical trials 95%100% 
of susceptible persons aged 12 months and older developed rubella antibodies 
by 2128 days after vaccination. Vaccination even at nine months of age 
results in seroconversion rates of more than 95%. Vaccine-induced immunity 
is generally assumed to be lifelong, although rubella antibodies may fall below 
detectable levels.  
SEROSURVEILLANCE OF RUBELLA AND CRS (17) 
The WHO has issued guidelines for surveillance of rubella and CRS. 
For countries that wish to assess whether to add rubella vaccine to their 
national immunization programme, baseline information on the disease burden 
due to CRS may be helpful. 
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There are several options for assessing the disease burden due to CRS: 
1. Carry out CRS surveillance for at least two years, either 
nationwide or in selected urban and rural populations where 
there are at least 200,000 births per year. 
2. When a rubella outbreak is detected, conduct investigations, 
including laboratory tests, of a small number of suspected rubella 
cases per month (perhaps 5 to 10 investigations per month). All 
febrile rash illnesses in pregnancy should be investigated. If 
rubella cases are reported in individuals > 15 years of age, active 
surveillance should be conducted until nine months after the end 
of the outbreak to identify suspected CRS cases in infants 0-11 
months of age. 
3. Conduct antenatal serosurveys to assess the proportion of women 
at risk for rubella infection in pregnancy. 
4. Where resources permit, conduct a community-based serological 
survey to estimate the potential CRS disease burden and the 
potential impact of different rubella vaccination strategies. 
5. Conduct serosurveys among women of childbearing age, which 
indirectly reflects the proportion of pregnant women at risk. 
Because the public health burden of rubella relates to the risk of 
infection of pregnant women, which in turn may cause CRS in their offspring, 
many countries have conducted serosurveys to determine the proportion of 
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women of childbearing age who are susceptible to rubella as it indicates the 
potential risk for rubella infection in pregnant women.   
A single cross-sectional survey of IgG seroprevalence in women of 
childbearing age is of limited usefulness in demonstrating disease burden. 
Although a high level (e.g. >20%) of susceptibility is likely to indicate a high 
risk of CRS in that population, a low level of susceptibility cannot be taken to 
mean no risk of CRS. Even when susceptibility levels in women are below 
10%, CRS can occur (20,21). Therefore serological surveys are of most use to 
monitor trends in the proportion of adult women who are susceptible, in 
particular in countries, which have introduced rubella vaccination for women 
of childbearing age. In special situations when financial and technical 
resources permit, a country can consider conducting an age-stratified 
serosurvey for rubella. However, this will be a major research study that 
requires the participation of a virologist whose laboratory is prepared to 
conduct large numbers of serological tests; one or more epidemiologists to 
design the study; staff to carry out the fieldwork; and a mathematical modeler 
experienced in studies of communicable diseases to analyze the results. This 
type of survey can provide point estimates (with confidence intervals) of the 
proportion susceptible to rubella for each age group surveyed. Such data, in 
conjunction with mathematical modeling, can be used to estimate the average 
age at rubella infection and to predict the effect of different immunization 
strategies on the incidence of CRS over different periods of time (22,23).   
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INTRODUCTION OF RUBELLA VACCINATION INTO THE 
NATIONAL PROGRAMME 
Once the baseline information on disease burden is available, strategies 
for introduction of rubella vaccination into the national immunization 
programme should be implemented.  
The immunization of boys and girls aged 1 year (childhood 
immunization) aims to protect women of childbearing age from exposure to 
the rubella virus by interrupting its transmission (24,25). This can lead to a 
rapid reduction in cases of congenital rubella and extension of the 
interepidemic period, but if vaccination coverage is low there is concern that 
this strategy may increase the incidence of rubella in susceptible adolescents 
and adults, thus increasing the incidence of congenital rubella. It has been 
estimated that in developed countries this could happen in the long term if 
immunization uptake was lower than 50%-60%, with wide oscillations in the 
incidence of congenital rubella in the medium term (24,26-29).  This shift in 
the proportion of susceptibles in older age groups can result in more cases of 
CRS than in the prevaccination period. Consequently, it is essential that 
childhood vaccination programmes achieve and maintain high levels of 
coverage. All countries undertaking rubella elimination should ensure that 
women of childbearing age are immune and that routine coverage in children 
is sustained >80%. 
In contrast, when immunization is targeted at adolescent girls or women 
of childbearing age (selective immunization), the epidemiology of rubella is 
largely unaffected since most infections occur before the age at immunization. 
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With such an approach, the incidence of CRS declines linearly with the level 
of coverage. However, elimination of CRS cannot be achieved with this 
strategy, in part because it would require every susceptible woman to be 
effectively immunized (30). Several countries have adopted a combined 
vaccination strategy because of its advantages (31). 
Countries wishing to adopt the selective immunization strategy should 
identify their target population. The precise target population addressed will 
depend on the susceptibility profile, cultural acceptability and operational 
feasibility. The most rapid impact would be achieved by mass campaigns for 
women of childbearing age (and men preferably). For increased impact even 
men should be vaccinated. In non-vaccinated individuals, susceptibility or 
immunity to rubella can be ascertained only by serological tests. However, 
serological testing is expensive and operationally impractical, and as there is 
no harm in vaccinating already immune individuals, serological screening for 
susceptibility is not recommended before rubella vaccination. 
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REVIEW OF LITERATURE 
Rubella IgG serosurveys among women of childbearing age indicate the 
potential risk for rubella infection in pregnant women. 
A review conducted by WHO in 1997 identified over 45 seroprevalence 
studies of rubella in developing countries conducted on women of child 
bearing age (32). The proportion of women who were seronegative to rubella 
was less than 10% in 13 countries (29%), 1024% in 20 countries (44%), and 
at least 25% in 12 (27%) countries, worldwide. 
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A comprehensive review of literature revealed 16 rubella serosurveys 
among Indian women. All the studies carried out in the 1990s and 
subsequently involved the use of Rubella IgG ELISA assays, whereas earlier 
studies utilized Haemagglutination Inhibition assays. 
All the serosurveys revealed susceptibility ranging from 5% to 45%, 
reflecting the large size of the country and the pattern of rubella virus in 
circulation. 
Study year 
and 
reference 
Location Test 
Group age 
(in years) 
Sample 
size 
Percent 
negative 
1970 (33) Urban Delhi HAI Women 15-34 137 15 
1970 (33) Rural Delhi HAI Women 15-34 124 28 
1973 (34) Calcutta HAI Women 15-25 176 43 
1973 (35) Chandigarh HAI Women 16-40 325 19 
1978-79 (36) Lucknow HAI Women antenatal 300 22 
1982 (37) Kerala HAI Women antenatal 536 25.9 
1984 (38) Vellore HAI Women antenatal 132 4 
1989 (39) Delhi HAI Women antenatal 603 31 
1990-91 (40) Vellore ELISA Women antenatal 931 11 
1991 (41) Hyderabad ELISA Women antenatal 274 5 
1995 (42) Delhi HAI Women 10-40  200 45 
1997-98 (40) Vellore ELISA Women antenatal 765 13 
2000 (43) Delhi ELISA Girls 9-12  140 10 
2002 (44) Madurai 
Coimbatore 
Tirunelveli 
ELISA Women 18-40 1000 12 
15 
21 
2003 (45) Amritsar ELISA Women 10-45 580 31.2 
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2005 (46) Delhi ELISA, 
HAI 
Women antenatal 5022 17 
2003 (47) Srilanka ELISA Women antenatal 620 24 
1987-88 (48) Pakistan ELISA Women antenatal 2000 16 
2001 (49) Iran ELISA Women antenatal 255 4 
2002 (50) Taiwan ELISA Women antenatal 1087 23 
 
ELISA = Enzyme Linked Immuno Sorbent Assay 
HAI     = Haemagglutination Inhibition test 
The largest study thus far in India was the serosurvey done at the 
National Institute of Communicable Diseases, Delhi, by Gandhoke L et al 
between 1988 and 2002. The study showed that 83% of normal antenatal 
women and 86% of antenatal women with bad obstetric history were immune. 
Immunity status among antenatal women from 1988 onwards showed a steady 
rise. While in late 1980s it varied from 49 to 72.33%, there was a steady 
increase in 1990s till the new millennium where it was 87 to 92 % (46). This 
study did not analyze the seroprevalence in girls who were between 10 and 15 
years. 
Other studies from the Indian subcontinental countries like Pakistan and 
Srilanka have estimated the seronegativity in antenatal women to be 16% and 
24% respectively (47,48). In Iran the susceptible population was about 4% 
(49) and in Taiwan about 23% (50). 
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INDIAN SEROSURVEYS IN THE PREFERTILE AGE GROUP: 
There have been a few Indian studies that assessed the seroprevalence 
of Rubella in schoolgirls. 
Sangita Yadav et al in 2000 serosurveyed 140 healthy girls aged 9-12. 
Ten percent of the girls surveyed were found to be seronegative. Following 
vaccination the seronegative girls seroconverted and geometric mean titre 
(GMT) of rubella antibodies rose in those girls who were already seropositive 
(43). 
Singla N et al in 2003 studied 580 women out of which 200 were in the 
prefertile age group (10-15 years).  There was an increasing trend in 
seropositivity from 64% in the prepubertal age to the maximum incidence of 
77.2% in the age group 26-35 years (peak fertility age). This was followed by 
a conspicuous decline to 59.3% beyond 35 years. A decline in the immune 
status with rising socioeconomic status was also observed (45).  
Bhaskaram P et al in 1991 serosurveyed 139 children aged 1-15 years 
for Rubella IgG antibodies by ELISA. Children between 1 and 5 years showed 
the lowest seropositivity of 69.2%, which gradually increased to reach near 
95% levels by 15 years (41). 
Yadav S et al in 1995 serosurveyed 40 girls in the prefertile age group 
1-5 years and 160 females of child-bearing age. 55% of the prefertile girls 
were seropositive for Rubella IgG. There was a gradual increase in the 
immunity status, with peak incidence of 66% between 30 to 34 years of age. 
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Females of low socioeconomic status showed higher incidence of immunity 
(63%) compared to social class I (40%) (42).   
Seth P et al in their study on seroepidemiology of rubella infection in 
female subjects of Delhi and its surrounding villages in 1971, showed that 
76.7% of the urban population and 64.3% of the rural population of girls 
between 10-14 were seropositive for Rubella IgG antibodies. In both urban 
and the rural population the seropositivity increased with age to reach a 
maximum between 25-34 years. But GMT of rubella IgG antibodies declined 
with increasing age and the antibody levels were 5-6 fold reduced at 25-35 
years when compared to 10-14 years (33). 
M.S Chakraborthy et al in their seroepidemiological study of rubella in 
Calcutta, done in 1976, showed that the seroprevalence in children of both sex 
at 11-15 years was 54.38%. There was no significant difference in sex 
distribution of positive sera. They had also shown a rising trend in 
seropositivity with increasing age. But GMT of rubella IgG antibodies did not 
vary significantly with increasing age. A study by the same author in 1973 had 
showed that the incidence of seropositivity to rubella was 53.14% in female 
subjects in the age group 12-25 years (34). 
Pal et al had conducted a serological investigation of rubella virus 
infection in and around Chandigarh in 1974. They had demonstrated a 
seropositivity of 62% in boys and girls between 10 and 15 years. They had 
also demonstrated a rise in the GMT of antibodies from 6 months to 15 years. 
Thereafter the titre showed a steady decline to reach a nadir at 35-40 years 
(35). 
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An overview of these studies fails to establish any specific trend in 
seroprevalence of rubella in India, probably reflecting high seropositivity 
during outbreaks of rubella and low seroprevalnce during quiescent 
interepidemic intervals. Despite problems with the data, these estimates lend 
further support to the assertion that rubella is an under appreciated problem in 
our country, with no official data to appreciate the disease burden. 
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STUDY JUSTIFICATION 
The public health importance of rubella relates to the teratogenic effects 
when rubella infection is acquired in the early months of pregnancy.   
The endemicity of rubella has been well established in India. However, 
no official data is available regarding the prevalence of acquired and 
congenital rubella infection as it is not a notifiable disease. About 50% of 
children acquire rubella antibodies by the age of 5 years and 80 to 90% 
become immune by 15 years. Studies from India and abroad have found that 
10-20% women in child bearing age are susceptible to rubella. Between 6-12% 
of babies born with congenital malformations or infections have serological 
evidence of rubella. These studies highlight the existence of rubella leading to 
fetal malformation and wastage.  
Despite a safe and effective vaccine being available for more than a 
decade in India, so far there has been no clear-cut policy regarding rubella 
immunization of children either at 15 months or young girls at 9-12 
years.Therefore the need for routine immunization to control rubella has not 
been duly recognized so far. But in a significant deviation from the National 
Immunization Schedule, the government of Tamil Nadu launched a pilot 
project in five districts to administer the measles, mumps and rubella (MMR) 
vaccine to children and the rubella vaccine to adolescent girls. The new 
immunization schedule was launched in one block each in Theni, Vellore, 
Tiruvannamalai, Cuddalore and Perambalur districts. Conceptualised under the 
World Bank-assisted ICDS project and executed by the Public Health 
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department, the vaccine (0.5 ml) will be administered through subcutaneous 
injection at anganwadi centres and schools.   
For a developing nation, like India, to take informed decisions on the 
incorporation of vaccines into the national programme, data on the burden of 
the disease as well as feasibility and likely impact of implementing different 
vaccination strategies needs to be assessed. 
It was therefore considered worthwhile to study the rubella 
seroprevalence rates in schoolgirls and to analyze the influence of variables 
like age, socioeconomic status, previous history of immunization, previous 
history of exposure to rubella, nutritional status and onset of menarche, on 
seroprevalence. The age group 10-15 years has been chosen as it represents the 
age that the vaccination strategy is likely to target. The seroprevalence in this 
age group also represents the likely seroprevalence in women who enter 
childbearing age. Thus an indirect estimate of CRS burden in the community 
can be arrived at. 
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AIM OF THE STUDY 
 
• To assess the overall seroprevalence of rubella in schoolgirls 
aged between 10 and 15 years. 
• To assess the influence of variables like age, socioeconomic 
class, immunization status, exposure to exanthematous illness, 
nutritional status and onset of menarche, on the seroprevalence 
of rubella antibodies at that age. 
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MATERIALS AND METHODS 
STUDY DESIGN 
The study conducted was a cross sectional survey. 
STUDY PLACE 
The study was conducted at three schools in Chennai city. 
1. Rani Meyyammai Girls Higher Secondary School 
2. Bharath Dass Matriculation Higher Secondary School 
3. Vanavani Matriculation Higher Secondary School 
The schools were chosen so as to include children from all 
socioeconomic strata. These three schools served a large and diverse 
population of the South of Chennai.   
STUDY PERIOD 
The study was conducted over a 1-year period from July 2004 to 
August 2005. 
STUDY POPULATION 
Inclusion Criteria:  
All girl children aged between 10 and 15 years were included in the 
study, subject to availability of consent. 
Exclusion Criteria: 
Nil 
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SAMPLE SIZE 
The Sample size for the study was calculated based on the following 
considerations: 
Estimated seropositivity in girls between 10 and 15 years: 15% 
Confidence interval = 95% 
 α   Error = 0.05  
 β   Error = 0.2 
Precision = 5% 
Calculated Sample size = 196.  
 
SAMPLING TECHNIQUE 
Stratified random sampling 
MANOUVRE 
After obtaining necessary permission from the respective school heads, 
the nature of the study and its implications were thoroughly explained to the 
children during the school assembly and a notice containing the same was 
dispatched to their parents. Those girls who had consented for the study were 
enrolled. We thus enrolled 196 schoolgirls between 10 and 15 years in the 
study.  
The girls were then made to fill a detailed questionnaire (appendix 1) 
which included details about their age; residence; per capita income, education 
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and occupation of the parents; past history of exposure to any exanthematous 
illness akin to Rubella or immunization with MMR/Rubella vaccine.  
Subsequently a general health awareness camp was conducted in their 
respective schools. In this camp the girls were screened clinically for any 
illness/morbidity and appropriate medical advice was given to them. The girls 
were also advised on genital hygiene and reproductive health. The height in 
meters and the weight in kilograms of the cases were also recorded. A note 
was also made of the age of onset of menarche in the questionnaire. At the end 
of the camp, blood was drawn for the study. 
Only girls with a documented evidence of immunization with 
MMR/Rubella, like a vaccination record, school record or a medical record, 
were considered to be immunized. An undocumented history alone was a not 
considered relevant.  
The study required documentation of any past history of fever 
associated with skin rashes. Excluded from this parameter was the diagnosis of 
chicken pox, which generally had a classical mode of presentation. A history 
of any other febrile illness with skin rashes, available, was noted. As per the 
WHO definition of suspected Rubella, associated findings like 
lymphadenopathy and arthalgia/arthritis was also noted. 
Socioeconomic stratification of the subjects was done as per modified 
Kuppuswamys Socioeconomic Status Scale (51,52). In the modified scale, the 
educational and occupational criteria remain the same. To modify the 
economic criteria, the All India Average Consumer Price Index for Industrial 
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Workers (CPI-IW) was noted for the current year (Indian Labour Journal, 
published by Labour Bureau, Government of India, Delhi). The conversion 
factor between the CPI-IW for 1976 (the year when Kuppuswamys scale was 
proposed) and the current year is then determined. 
Conversion factor = CPI-IW for current year / 60.04. 
Subsequently, all the income groups in the Kuppuswamys scale are 
multiplied with the conversion factor to get the appropriate income groups for 
the year under study. The CPI-IW for the year 2005 as on June 2005 was 529 
and the conversion factor determined was 8.81. This gave a modified income 
scale and a revised Kuppuswamys Socioeconomic Status Scale that 
incorporated these modifications was used in our study. 
SOCIOECONOMIC STATUS SCALE OF KUPPUSWAMY 
(INCLUSIVE OF REVISIONS) 
(A) Education Score 
1. Professional or Honours     7 
2. Graduate or Post-Graduate      6 
3. Intermediate or Post-High-School Diploma   5 
4. High School Certificate      4 
5. Middle School Certificate     3 
6.  Primary School or literate     2 
7. Illiterate       1 
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(B) Occupation Score 
1. Profession       10 
2. Semi-Profession      6 
3. Clerical, Shop-owner, Farmer    5 
4. Skilled worker      4 
5. Semi-skilled worker     3 
6. Unskilled worker      2 
7. Unemployed       1 
(C)  Modified Family Income Per Month (In Rs.) for 2005 
1. > 17600      12 
2. 8800 - 17599      10 
3  6600 - 8799      6 
4. 4400 - 6599      4 
5. 2650 - 4399      3  
6. 901 - 2649      2 
7. <900       1 
Total Score     Socioeconomic Class 
26-29      Upper (I) 
16-25   Middle  Upper Middle (II) 
11-15      Lower Middle (III) 
5-10   Lower   Upper Lower (IV) 
<5     Lower (V) 
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SAMPLE COLLECTION 
With strict sterile precautions 3 ml of venous blood was taken from all 
subjects of the study group, in a sterile graduated plastic tube. Sera from the 
collected samples were separated and stored at 20°C before being transported 
in an appropriate cold box to the Virology Laboratory at Kings Institute of 
Preventive Medicine, Guindy, Chennai for analysis. All the sera collected were 
analyzed for the presence of rubella specific IgG antibodies using ELISA.  
In the Virology Lab of Kings Institute of Preventive Medicine, IgG 
ELISA was done using a kit procured from Equipar, an Italian manufacturer of 
biological products. The sample analysis was done as per the manufacturers 
recommendations. 
Principle of the assay: 
Microplates are coated with purified and inactivated rubella antigens 
that in the first incubation capture specifically anti-virus antibodies if present 
in the sample. After washing out the other components of the sample, specific 
anti-rubella antibodies are detected with a goat anti-human IgG antibody, 
conjugated with peroxidase (HRP). The intensity of the color, generated by the 
enzyme on the substrate/chromogen mixture in the last incubation, is 
proportional to the content of anti-rubella antibodies in the sample. Results are 
calculated by means of a standard curve calibrated on the WHO standard, 
providing a quantitative determination of Rubella-specific IgG. 
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Values are expressed in IU/ml.  
Reactive sample (Positive test):  >15 IU/ml, 
Equivocal: 10  15 IU/ ml and 
Non-reactive (Negative Test): < 10 IU/ ml. 
  
STATISTICAL ANALYSIS 
As already mentioned, this study aimed at analyzing the seropositivity 
for rubella IgG in schoolgirls between 10 and 15 years and the variables that 
have an influence on the seropositivity. The proportion of outcome measures 
were calculated as percentages. 
Data were analysed using SPSS, version 13, to calculate mean, standard 
deviation and chi-squared values. A value of P < 0.05 was considered 
statistically significant. 
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OBSERVATIONS 
A total of 196 schoolgirls who had consented for the study were 
included and the following observations were made 
Table - 1 
 
Variable Frequency Percentage 
10 31 15.8 
11 21 10.7 
12 25 12.8 
13 26 13.3 
14 60 30.6 
Age 
15 33 16.8 
1 10 5.1 
2 50 25.5 
3 68 34.7 
4 65 33.2 
Socioeconomic class 
5 3 1.5 
None 157 80.1 
MMR 22 11.2 Past immunization 
Rubella 17 8.7 
No 144 73.5 Past history of 
exanthematous Illness Yes 52 26.5 
 
Table 1 gives the frequency distribution of the variables studied. All the 
ages had a fairly equal representation of cases except for girls at 14 years who 
represented 30.6% of the study population. A random selection of cases and 
the availability of consent are the reasons for the disproportionate 
representation of these girls when compared to other groups.  
45
 
The frequency distribution of cases as per Kuppuswamys 
socioeconomic status scale shows that classes 2, 3 and 4 constituted 25.5, 34.7 
and 33.2 percent of the cases respectively. Classes 1 and 5 were the least 
represented, constituting 5.1 and 1.5 percent of the cases. Majority of girls 
belonging to class 1 had not consented for the study resulting in their poor 
representation. There were very few girls belonging to social class 5 in the 
schools studied.  
The frequency distribution of cases based on previous immunization 
with MMR or Rubella is also tabulated. A total of 22 cases (11.2%) had 
received MMR and 17 cases (8.7%) had received rubella vaccination prior to 
the study. The rest of the cases (157 cases  80.1%) had neither received 
MMR nor rubella vaccine previously. Seventeen school girls between 14 and 
15 years belonging to Rani Meyammai school, had received rubella 
vaccination during a vaccination drive conducted by Lions Club, Chennai, two 
years prior to this study.  
A past history of fever with rash was present in 52 cases (26.5%) as 
given in table 1. Seven girls among them gave a history compatible with the 
WHO definition of Suspected rubella. None of them had been rubella 
confirmed. 
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ANALYSIS OF DATA 
Considering all age groups Rubella IgG seropositivity was found to be 
87.2%(171 cases) in our study. Twenty-three cases (11.7%) were Rubella IgG 
negative and in 2 cases (1%) results obtained were equivocal. 
  
87%
12% 1%
POSITIVE NEGATIVE EQUIVOCAL
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SEROPREVALENCE AND GEOMETRIC MEAN TITRE IN  
THE IMMUNIZED SCHOOLGIRLS 
 
TABLE - 2 
  
Result of Test 
Immunization 
Positive Negative Equivocal 
Total 
None 132 23 2 157 
MMR 22 0 0 22 
Rubella 17 0 0 17 
Total 171 23 2 196 
 
TABLE - 3 
 
Variable Number 
Seropositive 
(Percentage) 
P 
Unimmunized 157 84.1 
Immunized 39 100 
0.018 
 
Table 2 gives the distribution of seropositivity among immunized and 
unimmunized; and all the 39 vaccinated cases were seropositive (100%). 
Seronegativity and equivocal results were seen only among the unimmunized 
group. Twenty-two cases (11.2%) had received MMR and 17 cases (8.7%) had 
received rubella vaccination. Both set of girls who had received either MMR 
or rubella vaccine were seropositive. The difference in seropositivity among 
the immunized and unimmunized population as shown in Table 3 was 
statistically significant (P <0.05). 
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TABLE - 4 
 
Years elapsed since 
MMR vaccination 
Number GMT S.D P Value 
3 7 240 1 
4 7 202 2 
6 4 141 2 
9 3 48 2 
10 1 40 - 
0.000 
 
GMT = Geometric mean titre in IU/ml  S.D = Standard deviation 
 
0
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100
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3 4 6 9 10
NUMBER OF YEARS ELASPED SINCE 
RECEIVED MMR
GMT
 
Table 4 gives the Geometric Mean Titre (GMT) of Rubella IgG 
antibodies in girls who had received MMR vaccination in ascending order of 
numbers of years elapsed since vaccination. Out of the 22 girls who had 
received MMR, 7 each had been vaccinated 3 and 4 years back; 4 had been 
vaccinated 6 years back, 3 nine years back and 1 ten years back. An analysis of 
the table shows that the GMT was the highest in girls who had received the 
vaccine 3 years back (240) and the least in girls who had received MMR 10 
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years back.  The trend is better shown by the bar diagram which clearly reveals 
that the GMT of antibodies was highest in those who had received the vaccine 
3 years back, decreasing with numbers of years that had elapsed since 
vaccination, to reach a nadir in girls who had been vaccinated 10 years back. 
The difference in GMT was also statistically significant (p<0.05). 
TABLE - 5 
 
Vaccination Number GMT S.D P-Value 
MMR 22 146 2 
RUBELLA 17 279 2 
0.008 
 
GMT = Geometric mean titre in IU/ml  S.D = Standard deviation 
 
0
50
100
150
200
250
300
MMR RUBELLA
VACCINATION RECEIVED
GMT
 
Table 5 gives the GMT in girls who had received MMR and rubella 
vaccination. An analysis of the table reveals that the GMT of Rubella IgG 
antibodies was 146 IU/ml in girls who had previously received MMR against 
GMT of 279 IU/ml in girls who had received rubella vaccination previously. 
The difference in titer was also statistically significant (p<0.05).  
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TABLE - 6 
Unimmunized Immunized 
Age 
GMT S.D. GMT S.D 
P-Value 
10 87 6 196 2 0.04 
11 111 7 100 4 0.94 
12 97 4 135 3 0.61 
13 81 6 84 3 0.98 
14 49 5 260 2 0.02 
15 59 4 287 2 0.001 
 
GMT = Geometric mean titre in IU/ml  S.D = Standard deviation 
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Table 6 gives the GMT at different ages in both the immunized and 
unimmunized population. An analysis of the table shows that the difference in 
GMT at 10 years, 14 years and 15 years was statistically significant between 
the two populations whereas there was no significant difference in the GMT 
between the two populations at 11, 12 and 13 years. 
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SEROPREVALENCE AND GEOMETRIC MEAN TITRE IN THE 
UNIMMUNIZED SCHOOLGIRLS 
Out of the 157 schoolgirls who had neither received MMR nor Rubella, 
132(84%) were seropositive, 23(15%) were negative and 2(1%) were 
equivocal.  
 
15% 1%
84%
POSITIVE NEGATIVE EQUIVOCAL
 
   
Table 7 gives the distribution of geometric mean titres(GMT) and the 
seropositivity for the different ages and socioeconomic classes in the 
unimmunized population. The GMT and seropositivity in girls who had a past 
history of exanthemous illness is also given in the table. The GMT of 
socioeconomic classes 1 and 5 have excluded due to the insignificant numbers 
in them. 
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TABLE - 7 
 
Variable 
 N GMT Negative 
Seropositive 
Percent 
10 21 87 2 90.5 
11 19 111 3 84.2 
12 18 97 3 83.3 
13 23 81 2 87.0 
14 55 49 11 78.2 
Age in years 
  
  
15 21 59 2 90.5 
1 1 - Nil 100 
2 36 47 6 77.8 
3 58 61 7 82.8 
4 59 101 4 88.1 
SE class 
5 3 - Nil 100 
Yes 43 72 6 81.6 Past H/o  
exanthem No 114 59 7 90.7 
 
N = Number 
GMT = Geometric mean titre in IU/ml 
SE = Socioeconomic class as per modified Kuppuswamys scale 
 
1. AGE 
The seropositivity at different ages varies from a maximum of 90.5% at 
10 years to a minimum of 78.2% at 14 years. The difference in seropositivity 
at different ages is not statistically significant (P>0.05). 
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The GMT in the unimmunized population shows a peak of 111 IU/ml at 
11th year. A gradual decline is seen from the 11th year onwards upto the 14th 
year when the nadir is reached only to rise again at 15 years. The difference in 
GMT at 11 years is statistically significant from the GMT at 14 years. 
2. KUPPUSWAMYS SOCIOECONOMIC CLASS.  
The seropositivity is maximal in the class 4 (88.1%), if classes 1 and 5 
are excluded. Also there is an increase seen in seropositivity from classes 2 to 
4 but this is not statistically significant. 
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An analysis of GMT of the different socioeconomic classes shows that 
there is a definite rise in GMT from 47 IU/ml for class 2, to 61 IU/ml for class 
3, to 101 IU/ml for class 4. The difference in GMT among the different classes 
was also statistically significant. 
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 3. PAST H/O EXANTHEMATOUS ILLNESS 
The seropositivity in girls who gave a past history of exposure to 
exanthemous illness was 81.6%. All the seven girls who gave a history 
compatible with the WHO definition of suspicious rubella were seropositive 
(100%). There is no statistical significance in the seropositivity among those 
who had a past history of exanthematous illness with those who did not have. 
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An analysis of GMT in the girls who had given a past history of 
exanthematous illness also showed that it was not significantly higher (p>0.05) 
than the GMT in girls who did not give one. 
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4.  BMI AND MENARCHE: 
An analysis of BMI and seropositivity revealed that there was no 
significant correlation between the BMI and seropositivity in the study 
population as a whole and in the unimmunized population. (2-tailed 
significance of 0.220 for the entire study population and 0.316 for the 
unimmunized girls by Pearsons correlation). 
An analysis of correlation between seropositivity and onset of menarche 
was also done. Here too there was no statistical significance (P>0.05 for 
population as a whole and the unimmunized population) 
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DISCUSSION 
Rubella is a common worldwide infection; its importance in public 
health relates to the risk of malformations when primary infection occurs 
during pregnancy. 
Interest in the burden of disease and rubella vaccination policies has 
increased recently for a number of reasons.  
• Even though rubella outbreaks leading to CRS have not been 
documented in India, outbreaks in different parts of the world like in 
Panama in the mid-1980s, and in Oman and Sri Lanka in the 1990s 
have highlighted the importance of rubella. 
• Measles vaccine coverage of infants is now >80% in many parts of 
India; thus effective rubella control programmes are feasible. 
• MMR vaccine is distributed in the private sector.  A recent publication 
provides details of an increase in CRS incidence in Greece that may 
have resulted from the misuse of rubella vaccination strategies (53). 
Rubella vaccine was introduced in Greece in 1975, mainly as MMR 
vaccine provided for children in the private sector, and coverage 
remained consistently below 50% in the 1980s. The proportion of 
women of childbearing age susceptible to rubella gradually increased. 
In 1993, the country experienced a large rubella outbreak with 69% of 
cases in persons >15 years of age. Sadly, 25 CRS cases occurred, and 
this is thought to be the largest CRS epidemic in Greece since 1950. 
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Vynnycky E et al also highlighted the danger of unmonitored 
immunization in the private sector (54). 
There is thus a need to review the principles and practice of control of 
rubella and CRS. 
Two approaches are recommended for CRS prevention  prevention of 
CRS only (through immunization of adolescent girls and/or women of 
childbearing age), and elimination of rubella as well as CRS (through 
universal vaccination of infants with/without mass campaigns, surveillance, 
and assuring immunity in women of childbearing age). Decisions on which 
approach is taken should be based on the level of susceptibility in women of 
childbearing age, the burden of disease due to CRS, strength of basic 
immunization programme as indicated by routine measles coverage, 
infrastructure and resources for child and adult immunization programmes, 
assurance of injection safety, and other disease priorities. 
As CRS is not yet a notifiable disease in our country, data on CRS is 
scarce and the exact prevalence of CRS is not yet known. Because of the 
difficulty in conducting population-based studies of CRS incidence, many 
studies have estimated the proportion of defects such as congenital 
malformations, blindness or deafness caused by CRS, rather than the rate per 
1000 live births. Extrapolating from these studies, rubella has been linked to 
the etiology of 26% of cataracts, 7-12% of congenital malformations and upto 
29% of sensorineural hearing deficits in infants in India (55-58). Unpublished 
studies done in our own hospital have demonstrated 14% seropositivity for 
rubella among suspected CRS cases. 
58
 
When data on CRS is scarce, assessment of disease burden can be made 
with the help of serosurveys in pregnant women and women of child bearing 
age. Because of the difficulty in clinical diagnosis, serological tests have 
become the mainstay of diagnosis of acquired Rubella.  
In this study, serological analysis for IgG antibodies was done by 
ELISA. ELISA scores over Haemagglutination-Inhibition test (HAI) in its 
ability to detect low levels of rubella antibody that are undetected by HAI. 
HAI is also a labour-intensive test associated with both false positive and false 
negative results (59). A value of <10 IU/ml was taken as the threshold for 
negative serology and a value between 10 and 15 IU/ml as equivocal, as per 
the recommendations of the kit manufacturer. But recently a few studies have 
questioned these values. In 1997 Matter et al in his study on the serum levels 
of rubella virus antibodies indicating immunity, observed that, limiting the 
threshold for immunity as <15 IU/mL entails the risk of withholding rubella 
vaccination from susceptible persons and  that only a subject having an anti-
Rubella IgG concentration higher than 20 IU/ml is immunologically protected 
(60). Nevertheless the recommendations of the kit manufacturer have been 
followed, in the absence of any consensus statements. 
There is considerable variation in the prevalence of rubella antibodies 
among women. European women have relatively higher prevalence of rubella 
immunity (93.2%) as compared to women of African (86.7%) and Asian origin 
(78.4%) (32). In India as reported earlier in the literature review, the figure 
ranges between 54% and 95%. The findings in this study of 87.2% fall within 
this range.  
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  This study included a sizeable number of girls who had previously 
received MMR vaccine or rubella vaccine at various ages. This makes the 
study unique and different from all the other studies done in the Indian 
population so far. This study included 22 girls who had received MMR 
vaccine and 17 girls who had received rubella vaccine. All the girls who had 
been vaccinated previously were seropositive at the time of the study in 
contrast to only 84.1% of the unimmunized girls who were found to be 
seropositive. The GMT of Rubella antibodies at certain age groups among 
immunized girls was also significantly higher than in the unimmunized 
population at the corresponding age.  
In India, MMR and rubella vaccine are manufactured by the Serum Institute of 
India in Pune. Rubella vaccine was first introduced in India in 1992 and MMR 
subsequently in 1993. Various studies from around the world have clearly 
demonstrated the superior efficacy of MMR and rubella vaccines but studies 
from India, on their efficacy, are scarce. Yadav et al in 2003 evaluated the 
efficacy of MMR vaccine at 9 & 15 months of age. A total of 240 normal 
children, 120 each in the age group 9-10 and 15-18 months had been enrolled 
for the study. Of the 120 infants in the age group of 9-10 months, 102 (85%) 
were seronegative for measles and 96 (80%) were seronegative for both 
mumps and rubella before vaccination. Following MMR vaccination 92% 
were seropositive for measles, 100% for mumps and 98% for rubella. In the 
age group of 15-18 months, of the 120 children, 67 (56%) were seronegative 
for measles, 84 (70%) for mumps and 86 (71.6%) for rubella before 
vaccination. After MMR vaccination, seropositivity of 92, 96 and 94 percent 
was observed for measles, mumps and rubella, respectively. The rise in the 
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pre- and post-immunization geometrical mean titre was significant (P < 0.05) 
for each component of the vaccine in both the age groups. They had concluded 
that MMR vaccine could be offered safely and with equal efficacy to children 
at 9 and 15 months of age (61). 
Bhargava et al in 1995 studied the immunogenicity and reactogenicity 
of indigenously produced MMR vaccine in India. Studies were done on 89 
children already immunized for measles, between 15 to 24 months of age. : 
IgG positivity 4 weeks after immunization rose from 75% to 100% for 
measles, from 12% to 92% for mumps, and from 13% to 99% for rubella. Only 
mild side effects including pain and swelling in 37 (4.3%) cases, mild fever in 
51 (5.9%) cases, cough in 40 (4.6%) cases and a transient rash in 7 (0.8%) 
cases were observed (62).  
In this study the 22 girls who had received MMR had done so at 
different ages. All of them were seropositive for rubella IgG, but the GMT 
showed a gradual decrease with the number of lapsed years since vaccination. 
This difference was also statistically significant. 
Primary vaccine failure is known to occur in 2-5% of RA27/3 vaccine 
recipients, and a second rubella vaccination results in seroconversion in most 
cases (63-67). Antibodies have been found in 99.2% of schoolchildren after 
two doses of rubella vaccine, compared to 94.6% after one dose (68,69,70). 
Davidkin et al in their 15 year follow up study on the duration of rubella 
immunity induced by MMR vaccination in Finland had observed that upto 
31% of children who had received MMR at 14-18 months were seronegative 
compared to 9% and 0% in girls who had received MMR at 6 years and 11-13 
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years respectively (71). Picen Garces et al in their study on immunity to 
rubella in vaccinated children showed that 8.7% of children between 5 and 7 
years, who had received MMR at 15 months were seronegative. They also 
concluded that a high percentage of MMR vaccinated children showed 
minimal or undetectable levels of antibodies and thus merited a second dose of 
MMR to boost their immunity status (72).   
Thus a significant waning of rubella antibody titer in girls who had 
previous received MMR at 1 year of age, as shown in this study, could indicate 
a need for booster vaccination with either MMR at 4-6 years or with rubella 
vaccine at 10-15 years. This inference is also seconded by the observation in 
this study that GMT was significantly higher in those girls who had earlier 
received rubella vaccine when compared with those who had previously 
received MMR. Sangita Yadav et al in 2000 had also observed that following 
rubella vaccination the previously seronegative girls seroconverted and 
geometric mean titre of Rubella antibodies rose in those girls who were 
already seropositive (43). 
Inspite of the non-inclusion of MMR in the immunization schedule in 
our country, it had gained widespread usage in the private sector. The Indian 
Academy of Paediatrics recommends a dose of MMR in its schedule to all 
children at 12-15 months and presses for its inclusion in the national 
immunization schedule. Usage of MMR in the private sector has made it 
accessible to the elite section of the society but because of prohibitive costs 
and unavailability in government hospitals, it still remains out of reach of the 
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common man. This situation is also reflected in this study with only girls 
belonging to socioeconomic classes 1 and 2 having received MMR.  
After the implementation of the pilot project of rubella vaccination in 
schoolgirls by the Govt of Tamil Nadu, there has been resurgence in the 
interest in rubella. Many non-governmental organizations have taken to rubella 
vaccination drives in schoolgirls. This has resulted in the vaccination of 
schoolgirls from lower socioeconomic classes. The 17 girls in our study, who 
had received Rubella vaccine, had done so during one such drive.  
In the absence of previous immunization a number of other variables 
are known to affect the seropositivity. Socioeconomic status was reported to 
influence seropositivity by a number of Indian studies with a higher 
seropositivity seen among the lower socioeconomic classes (42,45). But the 
findings in this study had failed to demonstrate any significant change in 
seropositivity among socioeconomic classes. But what was significant was the 
increase seen in the GMT of Rubella antibodies in lower socioeconomic 
classes. The increased GMT in the lower socioeconomic classes could reflect 
the problem of overcrowding, adverse living condition, poor hygiene and 
environmental conditions, that results in easy transmission of infection from 
one individual to another.   
A past history of exanthematous illness was present in 52 girls (26.4%). 
The seropositivity in girls who gave a history of exposure to exanthematous 
illness was also not significantly different from those who had not given such a 
history. This only confirms the fact that Rubella is very difficult to diagnose 
clinically. Many studies have reported that a positive history of rubella 
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infection is substantially less likely to correctly predict rubella immunity than 
is a positive history of vaccination; therefore a history of infection is not 
adequate for determining susceptibility (69,73,74,75). 
This study also analyses the influence, if any, of the nutritional status of 
the subject and the onset of menarche with seropositivity of rubella but fails to 
establish any significant correlation.  
ECONOMIC IMPACT OF CRS AND THE NEED FOR RUBELLA 
VACCINATION 
Vaccines are important preventive medicines for primary health care, 
and are a critical component of a nation's health security. Although 
international agencies such as the World Health Organization (WHO) and the 
United Nations Children's Fund (UNICEF) promote global immunization 
drives and policies, the success of an immunization programme in any country 
depends more upon local realities and national policies. This is particularly 
true for a huge and diverse developing country such as India, with its 
population of more than 1 billion people, and 25 million new births every year. 
Case series studies have showed that approximately 70% of patients 
with CRS had cardiac abnormalities, 60% had low birth weight, 60% had 
hearing loss and 45% had cataracts (76). Since rubella vaccine adds to the cost 
of immunization, and additional efforts are required to ensure that women of 
childbearing age are protected, concerns about the costbenefit and cost
effectiveness of rubella vaccination assume considerable importance. These 
concerns may be heightened because many of the benefits of rubella 
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vaccination of children occur after adulthood has been reached, rather than 
relatively quickly, as with measles or polio vaccines. Furthermore, the 
elimination of rubella may require the vaccination of adolescent and adult 
males as well as females in order to ensure that transmission is interrupted.  
Cost of treating a case of CRS is exorbitant (77). Kommu & Chase (78) 
estimated that the lifetime cost for treating a child with CRS in Barbados 
would be approximately US$ 50,000 and that lifetime costs of treating CRS 
cases from 1997 to 2012 in the absence of rubella immunization would exceed 
US$ 5.2 million. In Guyana, Kandola (79) estimated that the lifetime cost for 
treating a case of CRS would be US$ 63,990. Extropolating these data for a 
country like ours could be misleading; nonetheless, managing a case of CRS in 
India is not expected to cost any less. In addition to medical costs, many of the 
complications of CRS prevent people afflicted with the disease from entering 
the workforce, resulting in a significant loss of productivity to society. The 
medical costs could include the expenses for hospital visits and diagnostic 
investigations, the purchase of pharmaceuticals, special schooling, the surgical 
repair of congenital heart defects, the removal of cataracts, fitting hearing aids 
for deafness, so on and so forth. Indirect costs may include the loss of lifetime 
earning potential, attributable, for example, to irreversible blindness, 
congenital deafness, intractable seizures, mental retardation and/or premature 
death, and the loss of the potential wages of childrens carers. It is difficult to 
make intercountry comparisons in this respect because the costs of health care 
and the monetary value of lost human productivity vary widely among 
countries. 
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The average life expectancy of an Indian is 64.35 years. In addition the 
2004 estimate of Gross Domestic Product (GDP) per worker in India was 
$3,100. Estimating an average working lifetime of 54.35 years (assuming a 
child begins to work at 14 years of age), India would stand to lose US$ 
1,68,485 in productivity for each person infected with CRS, assuming they 
would not enter the work force. The previously mentioned costs address only 
the financial burden to society of CRS children. The emotional costs to parents 
and society, while immeasurable, are significant and must also be considered. 
In 1996, UNICEF discounted the price of vaccines for the developing 
countries. The prices were US$0.15 (monovalent rubella vaccine), US$ 0.55
0.59 (MR vaccine), US$ 0.720.95 (MMR vaccine) (J. Gilmartin, personal 
communication, 1996). 
Using this estimate, one can calculate the cost of preventing one case of 
CRS by using the following equation: 
(100 000 live births/CRS incidence per 100 000 live births)  (cost of 
vaccine/dose). 
In this equation, the "(100 000 live births/CRS incidence per 100 000 
live births)" term gives the number of uninfected infants born for each infant 
born infected with CRS. This value is equivalent to the number of uninfected 
mothers per infected mother, and thus, the number of mothers that would need 
to be immunized in order to prevent the birth of one CRS infant. The incidence 
of CRS in India is not exactly known. Data on the percentage of persons in 
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different age groups who are susceptible to rubella can be used in 
mathematical models to estimate the incidence of CRS. 
In 1999 Cutts et al published a paper Modelling the incidence of CRS 
in developing countries in the International Journal of Epidemiology (80). 
They calculated the mean CRS incidence in India to be about 123 per 100,000 
live births (range 44 to 275 per 100,000), from the seroprevalence of rubella in 
girls at 13 years. The wide range suggested was because of inter-regional 
variation in seroprevalence of rubella. 
If we were to apply these estimates to the above equation, the cost of 
preventing one case of CRS would be  
100,000 live births / 123      US $.15  = US$ 121.95 
Thus the cost of preventing one case of CRS in India would be about 
US$ 121.95. This figure would amount to about Rs.5246.  
Although these calculations are based on a number of assumptions and 
are in no way foolproof, the gross difference between cost of treating one case 
of CRS and the cost of preventing one case of CRS by vaccination, as 
suggested by the above calculations strongly suggests that a national rubella 
vaccination programme in India could be cost-effective. Non-vaccine costs 
have not been included, since a rubella immunization programme could easily 
be added to existing programmes for DPT, polio, BCG, and measles. This 
would require only a marginal increase in cost, as the personnel and supplies 
for vaccine administration in India are already funded.  
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A WHO bulletin on Economic analysis of Rubella and Rubella 
Vaccine in 2002 reported that all the cost benefit studies of rubella 
vaccination in developing countries indicate an excess of benefits comparable 
to those estimated for the use of Hepatitis B vaccine or Haemophilus 
influenzae type b (Hib) vaccine in these countries (77). The economic data 
given in this bulletin supports the inclusion of rubella vaccine in the 
immunization programmes of both developing and developed countries and 
indicate economic benefits comparable to those derived from the use of 
Hepatitis B vaccine and Hib vaccine.  
Although the estimates of CRS may be lower than the annual number of 
deaths from neonatal tetanus or pertussis, the life long disability associated 
with CRS presents a major burden to the individual, family and society. 
Rubella vaccine is more expensive per dose than Tetanus Toxoid or DPT 
vaccine but the administration costs are lower since only one dose is required 
and combined vaccination with measles and mumps can prevent extra cost of 
injection. Rubella vaccination is included in the national immunization 
programmme of a number of countries and territories of the world. According 
to a survey of the member countries in the World Health Organization, the 
number of countries that have incorporated rubella-containing vaccine into 
their routine national immunization programmes increased from 65 (33%) in 
1996 to 110 (57%) in 2003. The vaccines are highly protective and without 
significant adverse effects. Caring for CRS cases is costly in all countries. All 
cost-benefit studies of rubella vaccination, in developing and developed 
countries, have demonstrated that the benefits outweigh the costs and that 
rubella vaccination is economically justified, particularly when combined with 
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measles vaccine (all of these studies have been conducted in countries with 
coverage > 80%). Large-scale rubella vaccination during the last decade has 
drastically reduced or practically eliminated rubella and CRS in many 
developed and in some developing countries. 
Data from Tamil Nadu shows that the school going girl population is 
about 18.98 lakhs in the age group 11-14 with an enrollment percentage of 
91.15%. At 14-16 years school going girl population dips to 11.98 lakhs with 
also a dip in enrollment percentage to 70.12% (Source: 2004 statistics  
Department of School Education, Tamil Nadu).  This sharp fall in school 
going population has been attributed to various factors like attainment of 
menarche in girls at about 13 years and the stoppage of the government 
sponsored free mandatory education for children at 14 years. Also familial 
pressures for supplementation of income results in more school dropouts. 
Therefore vaccinating all school girls at 13 years before a dramatic dip in 
attendance rates occur, would be ideal. 
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SUMMARY AND CONCLUSION 
• The overall seropositivity for Rubella in schoolgirls between 10 and 15 
years was 87.2%. 
• 100 percent seropositivity was seen among girls who had received 
either MMR or Rubella previously. 
• Seropositivity of 84% was seen in the unimmunized 
• Difference in seropositivity among the immunized and the 
unimmunized girls was statistically significant. 
• Difference in GMT among the immunized and unimmunized girls at 
different age groups was also statistically significant. 
• The difference in seropositivity in the unimmunized schools belonging 
to different ages and socioeconomic classes was not statistically 
significant but the difference in GMT was found to be significant. 
• Past history of exposure to exanthematous illnesses, nutritional status 
and onset of menarche did not influence seropositivity. 
• The GMT showed a statistically significant decline with the number of 
years since vaccination with MMR. 
• The difference in GMT among the girls who had received MMR and 
Rubella vaccines was statistically significant 
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RECOMMENDATIONS 
All countries should assess their rubella situation and, if appropriate, 
make plans for the introduction of rubella vaccination. Although detailed 
surveillance and cost-benefit studies are not needed in every country before 
implementing rubella vaccination, the choice of policy in this regard requires 
some baseline information on the susceptibility profile of women of 
childbearing age (e.g. through serological studies of women). Findings in this 
study strongly advocate introduction of Rubella Vaccination into the national 
immunization programme targeting girls less than 13 years before a significant 
drop out in school attendance occurs. 
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ANNEXURE 1 - PROFORMA 
 
 
1. Name:  -----------      Ht: 
 
2. School studying  -----------      Wt: 
 
3. Age (in months): ------------  
 
4. Address:  ------------ 
 
5. 
Variable Father Mother Member 
1 
Member 
2 
Member 
3 
Name       
 
Education   
 
    
Occupation   
 
    
Income  
 
 
    
  
 
6. History of prior vaccination with MMR/Rubella vaccine: 
 
 MMR No of doses Rubella No of doses 
History  
 
   
When given     
 
       
 
7. Past history of exanthematous fever?      
  
 
 
  
 
8. Whether attained menarche?    
 
 
Yes No 
  
Yes No 
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